Claims for Patent: 10,130,681

✉ Email this page to a colleague

Summary for Patent: 10,130,681

Title:	Use of a VEGF antagonist to treat angiogenic eye disorders
Abstract:	The present invention provides methods for treating angiogenic eye disorders by sequentially administering multiple doses of a VEGF antagonist to a patient. The methods of the present invention include the administration of multiple doses of a VEGF antagonist to a patient at a frequency of once every 8 or more weeks. The methods of the present invention are useful for the treatment of angiogenic eye disorders such as age related macular degeneration, diabetic retinopathy, diabetic macular edema, central retinal vein occlusion, branch retinal vein occlusion, and corneal neovascularization.
Inventor(s):	Yancopoulos George D.
Assignee:	REGENERON PHARMACEUTICALS, INC.
Application Number:	US15471506

Details for Patent 10,130,681

Glossary

Show entries

Subscribe to access the full database, or Try for Free
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate

Regeneron Pharmaceuticals, Inc.	EYLEA	aflibercept	Injection	125387	November 18, 2011	⤷ Try for Free	2037-03-28
Regeneron Pharmaceuticals, Inc.	EYLEA	aflibercept	Injection	125387	August 16, 2018	⤷ Try for Free	2037-03-28
Regeneron Pharmaceuticals, Inc.	EYLEA HD	aflibercept	Injection	761355	August 18, 2023	⤷ Try for Free	2037-03-28
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

Showing 1 to 3 of 3 entries

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.